Personalized Psyciatric Assay

Patients suffering from psychiatric disorders vary widely in response to specific treatments, and poor response to one treatment does not necessarily imply poor response to others.

For example, among patients who do not benefit from initial treatment with one antidepressant, up to one-half experience significant improvement after switching to an alternative medication, adding a second medication, or adding psychotherapy.

Unfortunately, many patients treated in community practice, especially in primary care, have no chance to benefit from second-line treatments.

Accurate selection of the best initial treatment could have tremendous benefits for people living with psychiatric disorders.


Psychoassay is decision supporting tool based on novel molecular technologies which can guide selection of initial treatment:


  • To support you and your physician to plan an appropriate personalized treatment for psychiatric disorders like major depressive disorders, bipolar disorders and schizophrenia


  • To avoid unnecessary therapy


  • To predict patient’s response to psychiatric medications, like:

Amitriptyline, Aripiprazole, Atomoxetine, Citalopram, Clomipramine, Clozapine, Desipramine, Diazpam, Escitalopram, Fluoxetine, Fluvoxamine, Haploperiodole, Imipramine, Maprotiline, Nefazodone, Nortriptyline, Olanzapine, Paroxetine, Perphenazine, Phenytoin, Risperidone, Sertraline, Thiorizadine, Trazadone, Trimipramine, Venlafaxine, Zolpideme, Zuclopenthixol.

How it works:

Please send 10 ml EDTA-Blood or extracted DNA, patient’s request and consent forms 

Personalized Medicine

Regenerative Medicine

Stem Cell Technologies

Druckversion Druckversion | Sitemap
© P7medicine